ABSTRACT
The hepatitis B virus (HBV) is one of several viruses
responsible for viral hepatitis. In the world, more than 2 billion people have
been infected with HBV and more than 350 million of them have chronic
infection. Serological markers are used to confirm the diagnosis and / or
assist in the prognosis of acute infection or chronic HBV. The main marker of
HBV infection is the presence of the envelope antigen (HBsAg). Although holders
can eliminate the HBsAg and develop anti-HBs, it seems there is always a risk
of serious liver complications. The antigen HBV e (HBeAg) is generally used as
a marker and indicates a secondary active replication of HBV associated with a
progressive liver disease. Therefore, this marker may have limited interest in
monitoring the disease. The HBV DNA has a prognostic value with regard to the
development of acute and chronic infections. However, in developing countries,
the structures of molecular biology are almost nonexistent. Thus, we undertook
this study to evaluate the use of dried blood spot, with a view to achieving
PCR HBV.
We conducted a cross-sectional study, to prospective data
collection, comparing the one hand the conditions of conservation of samples
(room temperature and -20 ° C) and other types of samples (whole blood and
plasma). These samples came from 20 subjects HBs Ag positive, selected among
blood donors Center inter-departmental Pointe Noire.
The extraction method in Phenol chloroform is more sensitive
than using the commercial Qiagen kit. The difference was not significant in
regard to returns extraction method using phenol chloroform, whatever the type
of sampling and whatever the method of preservation of samples.
The use of blood dried on blotting paper is a simple and
effective method in molecular diagnosis of HBV infection.
Key words: HBV, dried blood spot, Viral
DNA
REFERENCES
1. De Francis R, Hadengue A, Lavanchy D, Lok ASK et
al. International Consensus Conference on Hepatitis B: Consensus
statement. J Hepatol 2003; 39 (1): S3-25.
2. World Health Organization 2000. Hepatitis B. Fact Sheet
WHO/204 (revised October).
3. Yala F, Olembe C, M'Pele P, Rosenheim M. Portage de
l'antigène HBs, d'anticorps anti-VIH, et de leur association chez
les donneurs de sang à Brazzaville. Bull Soc Pathol Exot 1988 ;
81 : 32-39.
4. Taty-Taty R, Yala F. Carrier state for HBs antigen and HBc
antibody in Brazzaville (Congo): sero-epidemiological study in the hospital and
non hospital environment. Bull Soc Patho Exot 1990; 83 (2); 149: 149-154.
5. Ibara JR, Itoua-Ngaporo A et al. Serological
markers of hepatitis B virus in hospitalized patients (Gastroenterology and
Internal Medicine Service of the University Hospital Center of
Brazzaville-Congo). Med Trop 1991; 51 (1):9-13.
6. Jardi R, Buti M, Rodriguez-Frias F et al. The
value of quantitative detection of HBV-DNA amplified by PCR in the study of
hepatitis B infection. J Hepatol 1996; 24:680-685.
7. Ranki M, Schatzl HM, Zachoval R et al.
Quantification of hepatitis B virus DNA over a wide range from serum for
studying viral replicative activity in response to treatment and in recurrent
infection. Hepatology. 1995; 21:1492-1499.
8. Mason AL, Xu L, Guo L et al. Molecular basis for
persistent hepatitis B virus infection in the liver after clearance of serum
hepatitis B surface antigen. Hepatology. 1998;
27:1736-1742.
9. Saito T, Shinzawa H, Uchida T et al. Quantitative
DNA analysis of low-level hepatitis B viremia in two patients with
serologically negative chronic hepatitis B. Journal of Medical Virology.1999;
58:325-331.
10. Nagata I, Colucci G, Gregorio GV et al. The role
of HBV DNA quantitative PCR in monitoring the response to interferon treatment
in chronic hepatitis B virus infection. J Hepatol 1999;
30:965-969.
11. Hadziyannis SJ, Manesis EK, Papakonstantinou A. Oral
ganciclovir treatment in chronic hepatitis B virus infection: a pilot study. J
Hepatol 1999; 31:210-214.
12. Blumberg B S. Encyclopédie Microsoft Encarta 2003.
Product ID: 59578- OEM-1207047-69207. Version: 12.0.0.O602.
13. Lee WM et al. Hepatitis B virus infection. N Engl
J Med 1997; 337: 1733-45.
14. Leroy V, Zarski JP. Virus de l'hépatite B.
Virologie Moléculaire Médicale. Collection Génie
génétique G2. Editions Médicales Internationales 2001.
15. Fleury HJA. Virologie humaine. Edition Masson. 4eme
Edition 2004.
16. Lok ASF, Heathcote J, Hoofnagle JH. Management of
hepatitis B: 2000 Summary of a Workshop. Gastroenterology 2001;
120:1828-1853.
17. Hureaux JM, Nicolas JC, Agut H, Peigue-Lafeuille H.
Traité de virologie médicale. Edition ESTEM. 2003.
18. Halfon P, Pol S, Bourlière M, Courcambeck J, Cacoub
P. Résistance aux analogues de nucléosides dans le traitement de
l'hépatite B. Rev Med Interne 2003 ; 24 : 786-793.
19. Mahoney FJ. Update on diagnosis, management and prevention
of hepatitis B virus infection. Clin Microbiol Rev 1999; 12: 351-366.
20. Gombe MC. HBs antigen: maker of the relation between
hepatitis B virus and primary cancer of the liver: the situation in
Brazzaville. IARC Sci Publ 1984; 63: 221-226.
21. Castéra L, Dhumeaux D, Pawlotsky JM.
Hépatite virales chroniques B et C. Revu Prat 2001 ; 51 :
1247-1257.
22. Pol S. Epidémiologie et histoire naturelle de
l'Hépatite B. Revu Prat 2005 ; 55 : 599-606.
23. Marcellin P, Asselah T, Boyer N. Traitement de
l'Hépatite Chronique B. Revu Prat 2005 ; 55 : 624-632.
24. Liaw YF et al. Resultat of lamivudine trials in
Asia. J Hepatol 2003; 39: 111-115.
25. Wai CT, Fontana RJ. Clinical significance of hepatitis B
virus genotypes, variants and mutants. Clin Liver Dis 2004; 2: 321-352.
26. Halfon P, Pol S, Bourliere M, Cacoub P. les
génotypes du Virus de l'Hépatite B:implications cliniques,
épidémiologique et thérapeutiques. Gastroenterol Biol
2002 ; 26 :1005-1012.
27. Chu CJ, Lok ASF. Clinical significance of hepatitis B
virus genotypes. Hepatology 2002 ; 35 : 1274-1276.
28. Guettouche T, Hnatyszyn HJ. Chronic hepatitis B and viral
genotype: the clinical significance of determining HBV genotypes. Antivir Ther
2005; 5: 593-604.
29. Chu CJ, Keefe EB, Han SH et al. Hepatitis B virus
genotypes in the United States: results of a nationwide study. Gastroenterology
2003; 125: 444-451.
30. Chu CJ, Hussain M, Lok ASK. Hepatitis B virus genotype B
in associated with earlier HBe Ag seroconversion compared with hepatitis B
virus genotype C. Gastroenterology 2002; 122: 1756-1762.
31. Sanchez-Tapis JM, Costa J, Mas A, Bruguera M, Rodes J.
Influence of hepatitis B virus genotype on the long-term outcome of chronic
hepatitis B in western patients. Gastroenterology 2002; 123: 1848-1856.
32. Lacombe K, Massari V, Girard PM et al. Major role of
hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 2006;
20: 419-427.
33. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B
genotypes and the response to interferon therapy. J Hepatol 2003; 33:
998-1002.
34. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and
lamivudine resistance. J Hepatol 2002; 36: 303-304.
35. Westland C, Delaney W, Yang H et al. Hepatitis B virus
genotype and virologic response in 694 patients in phase III studies of
Adefovir Dipivoxil. Gastroenterology 2003; 125: 107-116.
36. Ministère de la Santé et de la Population.
Draft Plan National de Développement Sanitaire, Juillet 2005.
37. Jardi R, Rodrigues-Frias F et al. Usefulness of dried
blood samples for quantification and molecular characterization of HBV-DNA.
Hepatology 2004; 40: 133-139.
38. Vauloup-Fellous C, Dubreuil P, Grangeot-Keros L.
Optimisation du diagnostic rétrospectif de l'infection
congénitale à cytomégalovirus à partir de la carte
de Guthrie. Pathol Biol 2006 ; 54 :551-555.
39. Khelifa F, Thibault V. Les génotypes du virus de
l'Hépatite B dans l'Est algérien. Pathol biol 2008 ;
67 : 1054-1058.
40. Miehakanda J, Bourgarel J, Nereli BE, Teulieres L, Hillion
AM. Vaccination contre l'hépatite B d'une population a
risque en République Populaire du Congo. Med Afr Noire 1991 ;
38 : 651-669.
41. Elira-Dokekias A, Okandze-Elenga JP, Dzia-Lepfounzou A,
Parra HJ. Prévalence des marqueurs viraux majeurs chez les donneurs de
sang à Brazzaville. Gazette de la transfusion 2002 ; 177 : 4-6.
42. Mbanya DN, Takam D and Ndumbe PM: Serological findings
amongst first-time blood donors in Yaoundé, Cameroon: is safe donation a
reality or a myth? Transfus Med 2003; 13: 267-73.
43. Batina A, Kabemba S, Malengela R. Marqueurs infectieux
chez les donneurs de sang en République Démocratique du Congo.
Rev Med Brux 2005 ; 28 : 145-9.
44. Makuwa M, Bakouetela J, Bassindikila A, Samba-Lefebvre MC.
Etude des marqueurs sérologiques de l'hépatite B chez les
patients congolais testés pour l'infection à VIH. Méd Afr
Noire 1996 ; 43 : 198-200.
45. Fischer A, Lejczak C, Lambert C et al. Simple DNA
Extraction Method for Dried Blood Spots and Comparison of Two PCR Assays for
Diagnosis of Vertical Human Immunodeficiency Virus Type 1 Transmission in
Rwanda. J. Clin. Microbiol 2004; 42: 16-20.
| 
